Neumora Therapeutics, Inc.

Ladies and gentlemen, thank you for standing by. This is RG, your conference operator today. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. Please be advised that today's conference is being recorded. I would like now to turn the conference over to Helen Robinson, Vice President of Investor Relations and Communications. Please go ahead.

Good afternoon, and thank you for joining Numora Therapeutics' second quarter 2025 financial results conference call. Before we begin, I encourage everyone to go to the investors and media section of our website at numoratx.com, where you can find the press release related to today's call. With me today from Numora are Chief Executive Officer Paul Burns, President Josh Pinto, Chief Operating and Development Officer Bill Arora, Chief Scientific Officer Nick Brandon, and Chief Financial Officer Mike Milligan. I'd like to point out that we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. Please review the risk factors discussed in today's press release and in our SEC filings for additional detail. With that, I'll now turn the call over to Paul.

Thanks, Helen. Good afternoon, everyone, and thank you for joining us. At Numora, we are on a mission to address the largest population health challenges of our generation and to do so at scale. To achieve that goal, we know that we need to generate better medicines, therapies that enable better outcomes, that meaningfully improve the treatment of prevalent diseases, and ultimately that positively impact quality of life for patients and their families. With that aim in mind, We built an industry-leading pipeline targeting some of the most prevalent and burdensome brain diseases. Our approach is centered on advancing programs with best-in-class pharmacology targeting novel mechanisms of action with the potential to improve upon the current standard of care for hundreds of millions of people. We are proud to be making important progress toward that goal. Today we announced that we prioritized obesity as the lead indication for NMRA215, our highly brain penetrant NLRP3 inhibitor. An increasing body of evidence supports the need for the role of centrally acting drugs to drive weight loss and obesity, and NLRP3 inhibition in particular has shown promise across multiple studies. Importantly, Recent data suggests that molecules with high CNS penetration and activity are required for efficacy with this target. Currently, obesity and overweight affect more than 2.5 billion people globally. And by 2035, that number is expected to increase to up to 4 billion people. The need here is immense. Obesity is associated with significant negative outcomes and lower quality of life, and there is room to improve upon the efficacy and tolerability of the current generation of incretin therapies. In fact, up to a third of patients are non-responders to current therapies and do not experience clinically meaningful weight loss. Additionally, patients experience numerous on-target GI adverse effects and weight regain is common after patients stop taking these drugs. These challenges are highlighted by the real-world use data on GLP-1s. A recent real-world study found that 68% of people taking a GLP-1 for obesity discontinued use of their medication within one year. And research from the Blue Cross Blue Shield Association found that 58% of patients discontinued use before reaching a clinically meaningful health benefit. We believe that NLRP3 inhibition may offer an efficacious, well-tolerated treatment option for obesity, potentially as a monotherapy in combination with GLP-1 medications or as a maintenance treatment option. Our deep expertise in neuroscience and specifically in developing highly brain-penetrant chemistry makes pneumora uniquely positioned to bring a potential new mechanism to this large and growing public health challenge. The breadth of our pipeline and its potential impact is immense, and we are in a strong position to translate that science into real-world therapeutic breakthroughs. We expect to have up to six clinical data readouts in patients over the next 18 months, and I'm excited to continue to build on this momentum. I will now turn the call over to Josh Pinto, President of Nimora, to review our pipeline updates. Josh?